Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells $369,380.00 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) CAO Michael Megna sold 4,600 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $77.91 on Friday. The firm has a market capitalization of $6.08 billion, a P/E ratio of 80.32 and a beta of 0.09. The stock has a fifty day moving average price of $71.98 and a two-hundred day moving average price of $57.36. Kiniksa Pharmaceuticals International, plc has a 52-week low of $35.12 and a 52-week high of $82.94.

Get Kiniksa Pharmaceuticals International alerts:

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The business had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. On average, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on KNSA shares. The Goldman Sachs Group raised their price target on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Wedbush lifted their price target on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.38.

Check Out Our Latest Report on KNSA

Institutional Trading of Kiniksa Pharmaceuticals International

A number of large investors have recently made changes to their positions in KNSA. Corient Private Wealth LP raised its stake in Kiniksa Pharmaceuticals International by 26.8% during the 2nd quarter. Corient Private Wealth LP now owns 10,214 shares of the company’s stock worth $653,000 after buying an additional 2,158 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Kiniksa Pharmaceuticals International in the second quarter valued at about $256,000. California State Teachers Retirement System increased its holdings in shares of Kiniksa Pharmaceuticals International by 6,384.0% in the second quarter. California State Teachers Retirement System now owns 2,721,648 shares of the company’s stock worth $174,049,000 after acquiring an additional 2,679,673 shares in the last quarter. TD Waterhouse Canada Inc. increased its holdings in shares of Kiniksa Pharmaceuticals International by 4.5% in the second quarter. TD Waterhouse Canada Inc. now owns 16,691 shares of the company’s stock worth $1,049,000 after acquiring an additional 724 shares in the last quarter. Finally, Nykredit A S bought a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth about $34,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

(Get Free Report)

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.

See Also

• Five stocks we like better than Kiniksa Pharmaceuticals International
• Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
• Is Duolingo the Next Netflix-Style Comeback Story?
• GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
• GTA VI’s Console Problem Isn’t Take-Two’s Problem

Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.